Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | CKS1B | P61024 | 2/20 | 0.47 |
| ▸ | SKP1 | P63208 | 2/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 3/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333334 | 0.85 | HRH3 (0.56) | CKS1BSKP1SKP2LRRK2GPR119 | |
| SCHEMBL3268387 | 0.84 | LRRK2 (0.50) | FAAHCKS1BSKP1SKP2LRRK2 | |
| SCHEMBL3272042 | 0.84 | FAAH (0.61) | FAAHCKS1BSKP1SKP2GPR119 | |
| SCHEMBL20293573 | 0.84 | GPR119 (0.58) | CKS1BSKP1SKP2GPR119CCNT1 | |
| SCHEMBL3267984 | 0.83 | FAAH (0.59) | FAAHCKS1BSKP1SKP2GPR119 | |
| SCHEMBL29182809 | 0.82 | RET (0.44) | FAAHCKS1BSKP1SKP2LRRK2 | |
| SCHEMBL3268450 | 0.81 | FAAH (0.60) | FAAHCKS1BSKP1SKP2GPR119 | |
| SCHEMBL3269757 | 0.81 | FAAH (0.60) | FAAHGPR119CCNT1CDK9LMNA | |
| SCHEMBL3269653 | 0.81 | PDK2 (0.53) | FAAHCKS1BSKP1SKP2GPR119 | |
| SCHEMBL30124661 | 0.81 | CCNT1 (0.44) | FAAHCKS1BSKP1SKP2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885CKS1B 3175/4885SKP1 3469/4885 |
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885CKS1B 3175/4885SKP1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.